Imeik Technology: Distributor's Botulinum Toxin Product Recently Secures Drug Registration Certificate, Company Crafting Sales Strategy

Imeik Technology: Company Meets Diverse User Needs with Comprehensive and Differentiated Product Portfolio

Imeik's Botulinum Toxin Product Approved Amid Fierce Market Competition

Imeik Technology Development Gets Approval for Botox Injection; Shares Up 3%

"Medical Beauty Giant" Stumbles: Can Jian Jun Revive Imeik's Billion-Dollar Legend?

Imeik Tech Shifts from Leader to Laggard: Four Consecutive Quarters of Declining Performance, 1344% Premium Acquisition of "Youth Needle" Giant Entangles in $1.6B Agency Arbitration

From 19-Year Legal Career to Board Secretary of Imeik with 50 Billion Market Cap

Imeik Technology Development Says Board Elected Jian Jun as Chairwoman

BRIEF-Imeik Technology Development's Board Elects Chairwoman

Imeik Technology Development Co.,Ltd.: Product Sales and Operational Data Subject to Periodic Reports

From High Profitability to Growth Momentum: Imeik (300896.SZ) Builds a New Pattern of Diversified Development

Imeik Technology Faces Growth Slowdown: Q3 Revenue Drops 21% YoY to 570M Yuan, Adjusted Net Profit Falls 42% to 260M Yuan

BRIEF-Imeik Technology Development Q3 Net Profit Down 34.6% Y/Y

Imeik's Bold Move into Cosmetics Ingredients: What Does It Mean?

Controlling Shareholder Penalized for Insider Trading: Will "Hurun Rich List" Figure Be Cut Off by Hyaluronic Acid Giant?

Medical Aesthetics Leader Faces "Ice Age"! Imeik Technology's Quarterly Net Profit Plunges 42%, 1.6 Billion Yuan Arbitration Case Triggers M&A Crisis

Life-or-Death Battle Over Exclusive Distribution Rights for Dermal Fillers! Jiangsu Wuzhong Claims 1.6 Billion Yuan Against Medical Aesthetics Giant Imeik Technology

Core Business Growth Slows, Subsidiary Embroiled in Agency Rights Dispute - Imeik Technology Posts Double Decline in Revenue and Net Profit for First Half

Worst Semi-Annual Report Ever! Imeik's Revenue and Profit Both Decline, Sales of Solution/Gel Products Drop Significantly, Botulinum Toxin Project Delayed, High-Premium Acquisitions Lead to Goodwill Surge

Core Products Lose Momentum as Imeik Faces Biggest Test Since IPO